Welcome to our dedicated page for TransCode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a Boston-based clinical-stage biopharmaceutical company dedicated to combating metastatic disease through the discovery, development, and commercialization of novel microRNA (miRNA) therapeutics. The company's pioneering work centers around its proprietary TTX nanoparticle platform, designed to effectively deliver RNA-based therapies to target and treat various cancers.
The lead therapeutic candidate of TransCode Therapeutics, TTX-MC138, focuses on metastatic tumors that overexpress microRNA-10b, a well-known biomarker associated with metastasis. This candidate is currently undergoing rigorous clinical trials, with initial results indicating promising accumulation of the therapy in metastatic lesions.
The company also boasts a diverse pipeline of RNA therapeutic candidates, including TTX-siPDL1 and TTX-RIGA, aimed at overcoming the delivery challenges of RNA therapies and addressing novel genetic targets relevant to different cancer types. TransCode is actively engaged in expanding its research collaborations, as highlighted by its project combining the TTX platform with Debiopharm’s drug delivery technologies.
However, TransCode faces noteworthy financial and regulatory challenges. Recent communications reveal that the company is addressing compliance issues with Nasdaq listing requirements and the potential need for a reverse stock split to maintain its listing status. Despite these hurdles, TransCode remains committed to advancing its research and development efforts, securing strategic partnerships, and raising sufficient capital to drive its innovative pipeline forward.
TransCode’s vision extends beyond treating metastatic cancer; they aim to revolutionize cancer therapy by creating highly selective treatments that trigger the immune response against tumors while sparing healthy tissues. This approach is exemplified by their tumor-selective RIG-I agonists currently in development.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) announced a registered direct offering of 2,846,300 shares at $0.527 per share, aiming to raise approximately $1.5 million in gross proceeds. H.C. Wainwright & Co. is acting as the exclusive placement agent. The offering is expected to close around February 17, 2023, subject to standard conditions. The shares are being offered via a previously filed shelf registration statement with the SEC. This capital raise is intended to support the development of TransCode's RNA therapeutic candidates targeting various cancer types, including metastatic cancers, which are responsible for significant cancer mortality worldwide.
TransCode Therapeutics (Nasdaq: RNAZ) announced successful preclinical proof-of-mechanism studies for its immunotherapy candidate, TTX-RIGA, in melanoma, designed to activate innate immunity via RIG-I receptor binding. The studies showed promising results in delivering RNA-based agonists to tumors, potentially enabling tumor-selective immune responses. The company plans to advance TTX-RIGA to animal studies in February 2023. Furthermore, FDA has authorized a Phase 0 clinical trial for another candidate, TTX-MC138, targeting microRNA-10b in advanced solid tumors, with patient enrollment expected soon.
TransCode Therapeutics (NASDAQ: RNAZ) has received FDA authorization to commence its First-in-Human (FIH) Phase 0 clinical trial for TTX-MC138, targeting advanced solid tumors in up to 12 cancer patients. TTX-MC138 aims to inhibit microRNA-10b, a key player in metastasis. The trial will assess the delivery of the therapeutic to metastatic lesions and gather crucial pharmacokinetic data. Preclinical results indicate TTX-MC138's potential effectiveness in various cancers, demonstrating complete responses in animal studies. This marks a significant advancement for TransCode as a clinical-stage oncology company.
TransCode Therapeutics (NASDAQ: RNAZ) has withdrawn its Registration Statement on Form S-1, initially filed on November 28, 2022, due to unfavorable market conditions. The Company believes these conditions do not align with the best interests of its stockholders for a public offering. TransCode focuses on RNA-based cancer treatments, aiming to improve patient outcomes with its therapeutic candidates targeting various tumor types. Their lead candidate, TTX-MC138, aims to treat metastatic cancer, a leading cause of cancer deaths worldwide.
TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an exploratory eIND application to the FDA for a First-in-Human Phase 0 clinical trial of TTX-MC138, targeting advanced solid tumors. This therapeutic aims to inhibit microRNA-10b, a key player in metastasis. The trial will involve up to 12 patients to assess the safety and pharmacokinetics of TTX-MC138. Successful results could pave the way for further clinical trials and potential treatments for aggressive cancers like breast and pancreatic cancer.
TransCode Therapeutics (NASDAQ: RNAZ) reported Q3 2022 financial results, highlighting significant advancements in its RNA oncology pipeline. The company remains on schedule to submit an exploratory IND application for a Phase 0 trial involving TTX-MC138 in advanced solid tumors. Recently granted orphan drug designation for TTX-siPDL1 for pancreatic cancer emphasizes its focus on high-need areas. Financially, cash reserves decreased to $8.8 million, while R&D expenses surged to $3 million, reflecting ongoing investment in therapeutic development. The company expects funding will last through Q1 2023.
TransCode Therapeutics (RNAZ) announced positive preclinical results for its immunotherapy candidate TTX-siPDL1 in treating pancreatic adenocarcinoma. After two weekly treatments with TTX-siPDL1 and gemcitabine, tumor volumes were significantly reduced, with 75% of treated animals surviving compared to 25% for gemcitabine alone. The study demonstrated effective PD-L1 inhibition and immune activation. CEO Michael Dudley highlighted the platform's capability to overcome challenges in RNA delivery within tumors, marking a significant opportunity for the company.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation in the Sidoti Virtual Investor Conference on November 9-10, 2022. CEO Michael Dudley will present the company's advancements in RNA-based therapies targeting metastatic cancer, including its lead candidate TTX-MC138, which is entering first-in-human clinical trials. The presentation is scheduled for 2:30 pm ET on November 9 and will be available via webcast. TransCode aims to innovate cancer treatment through RNA therapeutics and has developed multiple candidates addressing various tumors.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) reported positive preclinical results for its lead candidate TTX-MC138 in treating pancreatic adenocarcinoma. The murine study showed a 40% complete response rate with treated mice and a successful pharmacodynamic response demonstrated by down-regulation of microRNA-10b. Further studies are underway to optimize dosing. TTX-MC138 has previously shown efficacy in breast cancer models, and the company plans to file an exploratory Investigational New Drug application for a Phase 0 clinical trial later this year.
TransCode Therapeutics (Nasdaq: RNAZ) announced the publication of a case study in Frontiers in Oncology regarding its lead therapeutic candidate, TTX-MC138. The study involved a feline patient with spontaneous metastatic breast cancer that had previously failed multiple chemotherapy rounds. TTX-MC138 demonstrated effective delivery to tumor cells via MRI and fluorescence microscopy. The patient experienced tolerable treatment and survived five months longer than expected, suggesting TTX-MC138's potential in advancing clinical trials for human metastatic cancer treatment.
FAQ
What is the current stock price of TransCode Therapeutics (RNAZ)?
What is the market cap of TransCode Therapeutics (RNAZ)?
What does TransCode Therapeutics, Inc. specialize in?
What is TTX-MC138?
What are the challenges TransCode Therapeutics is facing?
What is the significance of the TTX nanoparticle platform?
What recent project involves TransCode’s TTX platform?
What is the clinical status of TTX-MC138?
How does TransCode aim to innovate cancer therapy?
What are some other RNA therapeutic candidates in TransCode’s pipeline?
Who can I contact for more information about TransCode Therapeutics?
What are TransCode’s goals for 2024?
